Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurotech International ( (AU:NTI) ) just unveiled an announcement.
Neurotech International Limited reported a significant financial loss for the year ended June 30, 2025, with revenues down by 23% to $2.581 million and a 100% increase in losses, amounting to $10.599 million. The decline in revenue was primarily due to a decrease in R&D Grant Income, while the substantial loss was largely attributed to high research and development expenditure, which totaled $9.941 million. The company’s net tangible assets per ordinary security also fell from 1.17 cents to 0.28 cents, indicating a challenging financial period.
More about Neurotech International
Neurotech International Limited operates in the biotechnology industry, focusing on developing and commercializing neurological solutions. The company is involved in research and development activities aimed at creating innovative products to address neurological disorders.
Average Trading Volume: 811,694
Technical Sentiment Signal: Sell
Current Market Cap: A$13.65M
Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.